Triple meeting 2023 – Relay shifts to a tumour-agnostic plan
The company’s FGFR2 inhibitor shows potential beyond cholangiocarcinoma, but the markets aren’t buying it.
ESMO 2023 preview – J&J pulls a Mariposa rabbit out of the hat
And there won’t be a long to wait for the full data, with revelation that Mariposa features among numerous practice-changing late-breakers at ESMO.
AbbVie opt-out puts the focus on TeneoOne
The big pharma group had two anti-BCMA assets to choose from, and yesterday gave Harpoon the bad news.
World Lung 2023 – Flaura2 leaves a gap open for J&J
AstraZeneca’s trial lives up to its billing, though the benefit might be subgroup-driven, and comes at the cost of toxicity.
Exelixis claims a label-expanding Cabo success at last
However, the design of the Contact-02 study, and the relevance of the positive PFS endpoint, will be debated.
